association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a180 |
gain_cnaPANCAN280_(ARID4B,FH) |
1057 |
1 |
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
50 |
789 |
-1.386, 0.693 |
-2.49 |
-1.82 |
0.667 |
0.55 . |
0.56 . |
0.45 |
6.33e-05 |
8.18e-14 |
2.78e-02 |
5.8 |
a334 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1057 |
1 |
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
24 |
815 |
-1.386, 0.693 |
-2.47 |
-1.53 |
0.942 |
0.78 . |
0.79 . |
0.57 . |
3.02e-04 |
9.61e-14 |
2.81e-02 |
15 |
a336 |
loss_cnaPANCAN93 |
1057 |
1 |
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
87 |
752 |
-1.386, 0.693 |
-2.51 |
-1.91 |
0.605 |
0.5 . |
0.51 . |
0.47 |
3.09e-04 |
9.64e-14 |
2.81e-02 |
15 |
a369 |
loss_cnaPANCAN94 |
1057 |
1 |
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
89 |
750 |
-1.386, 0.693 |
-2.51 |
-1.92 |
0.593 |
0.49 |
0.5 |
0.47 |
3.77e-04 |
9.83e-14 |
2.81e-02 |
17 |
a390 |
loss_cnaPANCAN97 |
1057 |
1 |
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
92 |
747 |
-1.386, 0.693 |
-2.51 |
-1.93 |
0.581 |
0.48 |
0.48 |
0.48 |
4.33e-04 |
9.97e-14 |
2.82e-02 |
18 |